Impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis

This publication has 11 references indexed in Scilit:

• Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor/Tezacaftor/Ivacaftor initiation in a preadolescent with cystic fibrosis
  Journal of Cystic Fibrosis, 2022
• Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
  Canadian Journal of Ophthalmology, 2022
• Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients
  Pediatric Pulmonology, 2021
• 214: Improvement in fat-soluble vitamin levels following highly effective CFTR modulator use in children with CF
  Journal of Cystic Fibrosis, 2021
• The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status
  Nutrients, 2021
• CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
  Antioxidants, 2021
• Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis
  American Journal of Respiratory and Critical Care Medicine, 2020
• ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis
  Clinical Nutrition, 2016
• Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study
  The Lancet Respiratory Medicine, 2016
• Reference values for plasma concentrations of vitamin E and A and carotenoids in a Swiss population from infancy to adulthood, adjusted for seasonal influences
  Clinical Chemistry, 1997